Want to see AU:AGN full AI Analyst Report?
Total Valuation
Argenica Therapeutics Ltd has a market cap or net worth of AU$19.27M. The enterprise value is AU$32.86.
Market CapAU$19.27M
Enterprise ValueAU$32.86
Share Statistics
Argenica Therapeutics Ltd has 128,456,710 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding128,456,710
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Argenica Therapeutics Ltd’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -30.59%.
Return on Equity (ROE)-0.23
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-30.59%
Return on Capital Employed (ROCE)-1.20
Revenue Per Employee0.00
Profits Per Employee-195.05K
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Argenica Therapeutics Ltd is ―. Argenica Therapeutics Ltd’s PEG ratio is 0.11.
PE Ratio―
PS Ratio0.00
PB Ratio2.09
Price to Fair Value2.09
Price to FCF0.00
Price to Operating Cash Flow-4.29
PEG Ratio0.11
Income Statement
In the last 12 months, Argenica Therapeutics Ltd had revenue of 0.00 and earned -1.37M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit0.00
Operating Income-7.06M
Pretax Income-5.34M
Net Income-1.37M
EBITDA-7.06M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -4.19M and capital expenditures 0.00, giving a free cash flow of -4.19M billion.
Operating Cash Flow-4.19M
Free Cash Flow-4.19M
Free Cash Flow per Share-0.03
Dividends & Yields
Argenica Therapeutics Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.35
52-Week Price Change-46.15%
50-Day Moving Average0.17
200-Day Moving Average0.19
Relative Strength Index (RSI)41.39
Average Volume (3m)72.87K
Important Dates
Argenica Therapeutics Ltd upcoming earnings date is Mar 2, 2027, Before Open (Confirmed).
Last Earnings DateFeb 10, 2026
Next Earnings DateMar 2, 2027
Ex-Dividend Date―
Financial Position
Argenica Therapeutics Ltd as a current ratio of 10.60, with Debt / Equity ratio of 0.00%
Current Ratio10.60
Quick Ratio10.60
Debt to Market Cap0.00
Net Debt to EBITDA0.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Argenica Therapeutics Ltd has paid -3.97M in taxes.
Income Tax-3.97M
Effective Tax Rate0.74
Enterprise Valuation
Argenica Therapeutics Ltd EV to EBITDA ratio is -0.85, with an EV/FCF ratio of 0.00.
EV to Sales0.00
EV to EBITDA-0.85
EV to Free Cash Flow0.00
EV to Operating Cash Flow-1.42
Balance Sheet
Argenica Therapeutics Ltd has AU$6.36M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$6.36M billion.
Cash & Marketable SecuritiesAU$6.36M
Total DebtAU$0.00
Net CashAU$6.36M
Net Cash Per ShareAU$0.05
Tangible Book Value Per ShareAU$0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Argenica Therapeutics Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast81.00%